Ending HEU Use in Medical Isotope Production

In support of NTI's work to build an international consensus for the immediate reduction and phased elimination of highly enriched uranium (HEU) from the civil sector, a new paper by Anton Khlopkov and Miles Pomper, with Valeriya Chekina, develops a market-based roadmap for Russia to transition from HEU to LEU in the production of Molybdenum-99, which is used in 80% of the medical procedures involving isotopes. Such a plan would serve both an important nonproliferation function and contribute to the global security of Molybdenum-99 supply.

February 14, 2014
About

A new paper develops a market-based roadmap for Russia to transition from HEU to LEU in the production of Molybdenum-99, ahead of the 2014 Nuclear Security Summit.

Authors
Anton Khlopkov

Miles Pomper

Senior Research Associate, Center for Nonproliferation Studies

Countries